The CD44 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited human cell population engineered for targeted disruption of the CD44 gene. This polyclonal knockout product comprises a heterogeneous pool of loss-of-function cells derived from the Ca Ski cervical carcinoma line, offering a physiologically relevant system for studying CD44-dependent processes. The mixed genetic background circumvents clonal selection artifacts and captures population-level signaling variability often present in tumor microenvironments, making it a versatile platform for functional, biochemical, and pharmacological analyses.
Ca Ski cells originate from a metastatic site of a cervical squamous cell carcinoma isolated from a 40-year-old female patient. These epithelial cells harbor integrated human papillomavirus type 16 (HPV-16) sequences, a hallmark of high-risk HPV-driven transformation. Widely utilized in cervical cancer research, Ca Ski cells exhibit aggressive in vitro behavior, including robust migratory and invasive capacities, and serve as a standard model for investigating oncogenic signaling, HPV-host interactions, and therapeutic interventions against cervical carcinoma.
CD44 encodes a type I transmembrane glycoprotein that functions as the primary cellular receptor for hyaluronic acid (HA), a major glycosaminoglycan of the extracellular matrix. Upon HA binding, CD44 initiates signaling cascades involving PI3K/Akt and MAPK/ERK pathways, as well as Rho GTPases such as RAC1 and RHOA. Through interactions with ERM (ezrin, radixin, moesin) proteins and the actin cytoskeleton, CD44 coordinates adhesion, motility, and cytoskeletal reorganization. In malignancy, CD44 cooperates with growth factor receptors like ErbB2 and c-Met, and co-receptors such as LRP6, to amplify Wnt/??-catenin signaling. This receptor co-opts epithelial?Cmesenchymal transition (EMT) programs by transcriptionally upregulating Snail, Twist, and Vimentin, and by enhancing the activity of matrix metalloproteinases MMP2 and MMP9. CD44 is regulated by cytokines (IL-1??, TNF-??) and growth factors (EGF, HGF, TGF-??), positioning it at the nexus of inflammatory and tumorigenic signals.
Knockout of CD44 in Ca Ski cells is anticipated to impair hyaluronan-driven migratory and invasive phenotypes. Disruption of the CD44-HA axis likely attenuates PI3K/Akt-mediated survival and proliferation signals and reduces ERK1/2-dependent cell growth. The absence of CD44 may also diminish EMT effector expression and MMP activity, thereby weakening matrix degradation and metastatic potential. Given the HPV-16-positive background of Ca Ski cells, this model enables dissection of interactions between viral oncoproteins and host adhesion receptors. The polyclonal knockout population reflects heterogeneous gene disruption, mimicking the genetic diversity observed in tumors and making it suitable for bulk functional assays without clonal selection bias.
This CD44 knockout cell model supports diverse experimental applications, including tumor cell invasion and metastasis research, hyaluronan signaling studies, and drug target validation. Researchers can employ standard readouts such as Boyden chamber migration and Matrigel invasion assays, cell adhesion assays on HA-coated substrates, and immunofluorescence or flow cytometry for CD44 surface expression. Downstream signaling analysis via phospho-Akt or phospho-ERK western blotting, combined with MMP activity assays, permits comprehensive pathway perturbation assessment. These polyclonal knockout cells are particularly valuable for studying cancer stem cell properties and screening therapeutic candidates targeting CD44-dependent pathways. For further information or technical support, please contact Ascent Research.
